See more : American Premium Mining Corporation (HIPH) Income Statement Analysis – Financial Results
Complete financial analysis of Galectin Therapeutics Inc. (GALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galectin Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vibra Energia S.A. (VBBR3.SA) Income Statement Analysis – Financial Results
- Sailfish Royalty Corp. (FISH.V) Income Statement Analysis – Financial Results
- Pacific Gas and Electric Company (PCG-PA) Income Statement Analysis – Financial Results
- Third Point Investors Limited (TPNTF) Income Statement Analysis – Financial Results
- Eureka Design Public Company Limited (UREKA.BK) Income Statement Analysis – Financial Results
Galectin Therapeutics Inc. (GALT)
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.00K | 32.00K | 41.00K | 36.00K | 35.00K | 0.00 | 1.00K | 7.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 6.46M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -33.00K | -32.00K | -41.00K | -36.00K | -35.00K | 0.00 | -1.00K | -7.00K | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.33M | -6.46M | -7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.13M | 31.74M | 23.82M | 17.98M | 7.47M | 6.47M | 11.72M | 15.33M | 13.11M | 8.43M | 5.69M | 4.53M | 3.55M | 1.07M | 1.11M | 1.77M | 2.05M | 3.02M | 3.04M | 3.04M | 1.95M | 1.48M | 893.46K | 100.00K |
| General & Administrative | 5.90M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Selling & Marketing | 44.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.94M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Cost & Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Interest Income | 0.00 | 52.00K | 3.00K | 66.00K | 231.00K | 38.00K | 24.00K | 45.00K | 52.00K | 42.00K | 16.00K | 24.00K | 18.00K | 6.00K | 3.00K | 30.00K | 102.00K | 281.00K | 111.00K | 124.00K | 68.93K | 24.26K | 24.92K | 0.00 |
| Interest Expense | 2.56M | 1.03M | 489.00K | 87.00K | 87.00K | 336.00K | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 350.00K | 1.85M | 0.00 | 0.00 | 3.88K | 415.42K | 0.00 | 0.00 |
| Depreciation & Amortization | 38.07M | 32.00K | 41.00K | 36.00K | 35.00K | 1.00K | 1.00K | 7.00K | 7.00K | 10.00K | 12.00K | 9.00K | 9.00K | 12.00K | 37.00K | 49.00K | 64.00K | 67.00K | 81.00K | 81.00K | 89.17K | 211.18K | 159.47K | -20.00K |
| EBITDA | -202.00K | -37.71M | -30.00M | -23.34M | -13.17M | -13.56M | -16.23M | -21.47M | -20.07M | -15.78M | -12.08M | -9.67M | -10.91M | -5.62M | -7.43M | -3.10M | -9.02M | -1.28M | -6.77M | -7.10M | -4.85M | -3.08M | -2.02M | -190.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -38.07M | -38.35M | -30.18M | -23.44M | -13.44M | -13.60M | -16.25M | -21.48M | -20.08M | -15.43M | -12.10M | -9.90M | -10.41M | -4.88M | -6.09M | -5.33M | -6.46M | -7.05M | -6.66M | -7.30M | -4.94M | -3.29M | -2.18M | -170.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.99M | -424.00K | -348.00K | -21.00K | 144.00K | -298.00K | 12.00K | 45.00K | 52.00K | -358.00K | 16.00K | 224.00K | -506.00K | -746.00K | -1.37M | 2.18M | -2.98M | 3.86M | 111.00K | 124.00K | 65.05K | -391.16K | 0.00 | -20.00K |
| Income Before Tax | -41.07M | -38.78M | -30.53M | -23.47M | -13.29M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | 0.00 | -190.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 424.00K | 448.00K | 51.00K | 87.00K | -123.14K | 24.00K | 0.00 | 0.00 | -52.00K | 16.00K | 200.00K | 506.00K | 746.00K | 1.37M | -2.18M | 2.98M | -3.86M | 0.00 | 0.00 | 0.00 | 0.00 | 1.79M | 0.00 |
| Net Income | -41.07M | -39.20M | -30.98M | -23.52M | -13.38M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -3.97M | -190.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| EPS Diluted | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| Weighted Avg Shares Out | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
| Weighted Avg Shares Out (Dil) | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
Charting a successful technical test, S&P 500 nails the breakout point
GM to modify Tennessee plant to build electric vehicles
Tennessee factory to become GM's 3rd electric vehicle plant
GM announces $2 billion for electric vehicle factory in Tennessee, will build Cadillac LYRIQ and more - Electrek
Source: https://incomestatements.info
Category: Stock Reports